Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19)

Frontiers in Immunology(2020)10.3389/fimmu.2020.01451Source: DataRank Database

Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19) is a research paper published in Frontiers in Immunology (2020). On theSindex it has a DataRank of 0. It has been cited 514 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access514 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 48.47)OA: goldTopics (67)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Max Berrill ORCID,John D. Catravas ORCID,Paul E. Marik ORCID,Ruben Manuel Luciano Colunga Biancatelli ORCID

Live enrichment

PubMed:32636851 PMC:PMC7318306 OpenAlex:https://openalex.org/W3035876959

NIEHS NIH HHS

Grant: R21 ES030528

National Institutes of Health

Grant: 5R21ES030528-02

Antidotes against mustard-induced chronic lung injury

FWCI

48.47

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.01451/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.01451/pdf

publisherhttps://www.frontiersin.org/article/10.3389/fimmu.2020.01451/full

journalhttps://doi.org/10.3389/fimmu.2020.01451

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32636851

Fields of Study

Vitamin C and Antioxidants ResearchPhytochemicals and Medicinal PlantsPharmacological Effects of Natural Compounds0301 basic medicine03 medical and health sciences0303 health sciences

MeSH Terms

BetacoronavirusCOVID-19SARS-CoV-2COVID-19 Drug TreatmentAnimalsAntiviral AgentsAscorbic AcidDrug SynergismDrug Therapy, CombinationHumansImmunologic FactorsPneumonia, ViralQuercetinVirus ReplicationCoronavirus InfectionsMicePandemicsPre-Exposure Prophylaxis

Keywords

MedicineQuercetinContext (archaeology)Ascorbic acidImmune systemPandemicCoronavirus disease 2019 (COVID-19)DiseaseVitamin CIntensive care medicineVitaminPharmacologyImmunologyInfectious disease (medical specialty)AntioxidantBiologyInternal medicineFlavonoidsAntiviralCoronavirusImmunonutritionCovid-19Sars-cov-2Pneumonia, ViralVirus ReplicationAntiviral AgentsBetacoronavirusMiceAnimalsHumansImmunologic FactorsPandemicsImmunityDrug SynergismRC581-607COVID-19 Drug TreatmentImmunology of Infectious DiseaseVirus DiseasesDrug Therapy, CombinationPre-Exposure ProphylaxisPublic HealthImmunologic diseases. AllergyCoronavirus Infections

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19)

FAIR Checklist

Authors (4)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)